Why Bridgeline
We connect science, strategy, and capital. We turn early findings into practical choices, investable plans, and credible stories that partners and investors can act on.
Where we help most
Preclinical strategy. Translational planning. IND roadmaps. Investor and partner strategy and readiness.
Selected Outcomes
Clarified models and endpoints for a credible efficacy readout
Built a clean data room that sped investor review
Mapped IND studies with clear decision points and budget
Team
Leadership
Timothy S. Luongo, PhD- Principal
Timothy helped teams turn strong science into credible plans that investors trust and drive therapeutics and devices to the clinic. He led work across discovery, preclinical, and IND planning at startups and established pharma and biotech. He also led due diligence and supported external innovation and partnerships, giving him a strong understanding of what investors and partners look for in early-stage companies.
Advisory network
Bridgeline is supported by an on-demand network of subject matter experts. We bring the right people to each project, including investors, business development, pharmacology, toxicology, CMC, bioanalytics, statistics, regulatory, and clinical.